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Abstract 
BACKGROUND: Simultaneous occurrence of multiple primary melanomas is a rare, however possible 
phenomenon, and it is believed that older, male, white, Atypical Mole Syndrome carriers (sporadic and familial) 
are part of the possible risk factors for its occurrence. In these patients, it is possible to observe involutional 
changes or (partial/complete) regression of melanocytic lesions, which are likely to be caused by the generation of 
a spontaneous immune reaction against specific tumour antigens. 
CASE REPORT: A 58-year-old male patient is presented with two melanocytic lesions located in the right clavicle 
(subclavicular area) and left the scapular area that meets clinically and dermatoscopically the requirements for 
malignant melanoma. The lesions were removed by a radical excision with 0.5 cm surgical safety margin in all 
directions. During the subsequent histological verification it was established it was melanoma with a tumour 
thickness of 1 mm that in one case, and the other 2 mm. A week later, according to the recommendations of the 
current guidelines, a re-excision was performed with a surgical safety margin of 1.5 cm in all directions. 
Considering the complications that are possible during the parallel removal of a draining lymph node 
recommended for these tumour thicknesses, the patient definitively refused its detection and removal. 
CONCLUSION: A rare case of a Bulgarian patient with multiple primary, however partially involutional melanomas 
existing for over 20 years, is described. The individual recommendations of dermato-oncologists for the patient 
(according to AJCC) were not in favour of radicality but of a more sparing, individualised approach, appropriate for 
that patient. Unfortunately, the approach we used, in this case, was inconsistent with the AJCC or OSMS 
guidelines. The reason for individualising the approach in the case we have described is due to the variability of 
the recommendations for surgical treatment of melanomas laid down in the AJCC. 
 
 
 
 
 
 
 
 
 
Introduction 
 
The incidence of the so-called multiple 
primary melanomas (MPM) is between 1.3 and 8.0% 
[1]. The presence of primary melanoma increases the 
risk of subsequent development of the same 
melanocytic lesion, which most often occurs several 
years after the diagnosis of the primary formation and 
usually affects parts of the body that is different from 
its initial location [2]. The family history of malignant 
melanoma, as well as the presence of dysplastic 
nevus (in the relevant patient groups), are thought to 
be risk factors for MPM occurrence [1], [2], [3], [4]. 
These result in two interesting groups of patients with 
multiple primary melanomas: 1) within the so-called 
sporadic form of the syndrome of dysplastic nevi-AMS 
(atypical mole syndrome), 2) Familial atypical multiple 
melanoma (FAMMM) syndromes, 3) Xeroderma 
pigmentosum should also be considered a disease, in 
which there may be multiple primary melanomas, 4) 
Complete involution of malignant melanomas (MMs) is 
an extremely rare phenomenon; on the other hand, 
partial regression occurs in 10% to 35% of the cases, 
regardless of Breslow tumour thickness, 5) In this 
respect, clinical and histopathological criteria for MMs 
regression have been established [5]. Each patient 
with malignant melanoma or multiple primary 
melanomas should be considered a combination of 
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individual specificities that should determine the 
choice of strategy for subsequent treatment [6]. 
 
 
Case report 
 
A 58-year-old male patient is presented in 
good general status. The patient was hospitalised for 
the first time in Oncoderma Dermatology and 
Dermatologic Surgery Clinic, Sofia, for surgical 
removal of two pigment lesions located in the right 
clavicle (subclavicular area) and left scapular area. 
The lesions occurred 15 years ago, but within the last 
year, the patient has observed an increase in the 
intensity of the black colour and size of one of the 
lesions, as well as involution in the scapular area. 
During the dermatological examination, two 
melanocytic lesions with uneven boundaries and 
irregular distribution of the pigment were found in the 
right subclavicular and left scapular areas (Figures 1a-
1f).  
Clinically and dermatoscopically, these 
findings met the requirements for a malignant 
melanocytic lesion. Further tests were carried out: 1) 
paraclinical – without substantial changes, 2) lymph 
node ultrasound – no enlarged lymph nodes were 
visualized in the neck, two axil and inguinal area; 3) 
lung and heart radiology – preserved transparency of 
pulmonary parenchyma without active disease 
alterations – no focal changes were observed; clear 
costophrenic sinuses; heart shadow – normal, 4) S-
100-0.036 (< 0.1); LDH – 314.00 IU (240.00-480.00). 
 
Figure 1: a), b) Clinical picture of primary cutaneous melanoma 
located on the right- subclavicular. Lesion with uneven pigmentation 
and uneven boundaries; c), d) Clinical view of melanoma showing 
uneven pigmentation, uneven edges and data about involution 
located in the left scapular area; e), f) Outlining the 0,5 cm 
operational security boundaries in all directions, preoperative 
finding 
 
The lesion localised to the right, in the 
subclavicular area, was removed by radical excision. 
A surgical margin of 0.5 cm was used in all directions 
(Figure 2a). The resulting surgical defect was 
recovered by a single interrupted suture (Figure 2b). 
Histological verification showed that it was mixed, 
superficially advancing and nodular malignant 
melanoma, Clark’s level III, Breslow’s thickness 2 mm, 
no ulceration, high mitotic activity, moderate stromal 
lymphocytic reaction, no spontaneous regression, 
T2aN0M0 stage. 
In the left scapular area, a primary excision of 
the melanocytic lesion was performed with a surgical 
safety margin of 0.5 cm in all directions (Figure 2c). 
The defect was corrected using stretch plastics 
(Figure 2d). The histological examination of the lesion 
removed from the left scapular area showed 
superficially advancing malignant melanoma, Clark’s 
level II, Breslow’s thickness 1 mm, no ulceration, 
T1bN0M0 stage. 
 
Figure 2: a), c) Intraoperative finding of the two lesions removed by 
elliptical excision; b), d) Postoperative clinical picture of surgical 
defects closed by single interrupted sutures 
 
A week later, following the recommendations 
of the applicable guidelines, a re-excision was 
performed in the primary excision zones with 1.5 cm 
surgical safety margin in all directions (Figures 3a-3f). 
Immediately before the re-excision, the patient was 
consulted in the Oncology Ward, where the need for 
parallel removal of draining lymph node during the re-
excisions was rejected, based on 1) the lack of explicit 
evidence of locoregional dissemination of the process, 
2) complains that occurred more than 20 years ago, 
as well as 3) the involutional nature of one of the 
lesions. Postoperative period – calm, without 
complications. The patient was referred to the 
oncology unit for regular ultrasound controls and the 
introduction of systemic Interferon therapy. 
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Figure 3: a), d) Preoperative outline of 1.5 cm operational security 
boundaries in all directions for primary excision sites directly before 
re-excision; b), e) Intraoperative view of elliptical re-excision; c), f) 
Postoperative clinical picture of surgical defects closed by single 
interrupted sutures after re-excision 
 
 
Discussion 
 
Simultaneous occurrence of multiple primary 
melanomas (MPM) in the same patient is a rare, 
however well-recognisable phenomenon with variable 
incidence, according to the available literature [7], [8] 
[9], [10]. It is believed that older, male, white, history 
of melanoma, thin primaries and history of another 
cancer are risk factors for development MPMs [6], 
[10]. Also, the identification of Atypical Mole 
Syndrome carriers (sporadic and familial) is essential, 
as it is considered the most important phenotypic risk 
factor for cutaneous melanoma and there are 
documented cases of MPM within the familial and 
sporadic syndrome of dysplastic nevi [3]. 
MPM patients are also at risk of developing 
subsequent primary melanomas, which most often 
occurs within the first year [1], [10]. Apart from 
additional melanoma, the probability of developing 
nonmelanoma tumours in melanoma patients should 
be noted as well [11].  
It is interesting whether there is a difference in 
the prognosis between the patients with single and 
multiple primary melanomas [12]. So far, melanoma 
thickness, as well as some additional features, such 
as the presence of ulceration, mitoses and scalp 
location, has been used as a prognostic factor [12]. 
Based on the available literature from 
research, some conclusions have been laid down, 
without a unanimous opinion:  
1. According to some authors, the mean 
Breslow’s thickness of the first melanoma is 
significantly higher than the mean Breslow’s 
thickness of the second primary melanoma 
[13]. 
2. No difference is observed in the presence or 
absence of mitoses, a marker of tumour 
proliferation, in SPM (Single primary 
melanomas) and MPM [14]. 
3. CDKN2A mutation status and family history of 
melanoma significantly affect outcomes of 
MPM patients, and worse outcomes have 
been noted in patients with multiple primary 
melanomas (MPMs) than in patients with 
single primary melanomas [15]. 
4. Multiple invasive lesions seem more at risk of 
death than melanoma [16], but according to 
others: 
5. Thicker SPM, however, had higher fatality 
than thicker MPM [12], and 
6. The presence of multiple primary melanomas 
does not appear to be a negative prognostic 
factor [17].  
However, it is generally accepted that 
melanoma patients require close follow-up to detect 
not only metastases but also subsequent primaries in 
their earliest phases [17]. 
Spontaneous regression of malignant tumours 
is extremely rare, but it is still a possible phenomenon 
[18], [19], [20]. It may be partial or complete [21]. 
Regression is defined as a much more common 
phenomenon in cases of malignant melanoma than in 
other types of tumours [21]. It may typically be 
observed in patients with no evidence of metastases 
development, but also the event of metastatic 
melanomas [18], [20], [22]. While primary non-
metastatic melanomas are thought to have a possible 
spontaneous regression in up to 50% of cases, the 
percentage of metastases is quite different, and 
regression is only observed in 0.23% of the cases of 
metastatic forms [20], [21]. Clinically, the presence of 
hyper- to hypo-pigmented macules, patches, papules 
and plaques, measuring from 0.4 to 3.0 cm in 
diameter, showing enlargement, friability, and 
bleeding, speaks in favour of emerging regression [5]. 
In turn, histopathological signs defining the regression 
as an event include atrophic epidermis, dermal 
aggregation of many melanophages, lymphocytic 
infiltrate, reactive vascular proliferation, and 
surrounding fibrosis [5]. 
Regarding the factors considered as leading 
to spontaneous regression, surgical trauma, infection, 
vaccination (BCG and rabies vaccines), 
immunological factors, blood transfusion and various 
endocrine factors are being mentioned [21]. Now 
there is a widespread perception that specific cell-
mediated immunity against melanoma cells are 
involved in regression mechanisms and that mainly 
the lymphocytes are responsible for this tumour 
regression [19]. This has been investigated 
histologically and by immunofluorescence (direct and 
indirect) in the cases of Halo nevus, where it is clear 
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that in addition to T cell-mediated immunity (CD8 + 
cells outnumbered CD4 + cells), IgM antibodies 
against nevus cells as well as melanoma cells and 
cultured melanocytes may be involved in regression 
[23]. 
It is not yet clear how spontaneous immune 
response is induced and why, for example, in specific 
events of melanoma and congenital melanocytic 
nevus combination, regression only affects 
melanoma, while nevus remains undisturbed by the 
immunological response [24]. 
According to some authors, patients who 
develop multiple asynchronous melanomas, namely 
the first melanoma, produce an immunisation effect 
with increased immunity against certain antigens 
expressed by tumour-associated melanocytes [25]. 
According to other authors, the presence of 
regression may be considered a favourable prognostic 
factor in patients with AJCC stage I-II melanoma. 
However this statement is still controversial [26], [27]. 
The approach adopted for treatment of 
malignant melanoma includes surgical resection with 
adequate excision margins, with or without lymph 
node biopsy [28]. At this stage, a large proportion of 
dermatologists follow the recommendations of the 
American Joint Committee on Cancer, according to 
which primary melanoma surgery is based on Breslow 
tumour thickness and includes resection of 0.5 cm for 
MIS, 1.0 cm for melanomas ≤ 1.0 mm thick, 1-2 cm for 
melanoma thickness of 1.01-2 mm, 2 cm margins for 
melanoma thickness of 2.01-4 mm, and 2cm margins 
for melanomas > 4 mm thick [29]. Based on the 
established guidelines, treatment begins with 
resection of the melanocytic lesion with a surgical 
margin of 0.4-0.5 cm in all directions, followed by re-
excision (as in our patient) with or without parallel 
drainage lymph node (depending on the established 
postoperative tumor thickness), which however is not 
individualized and often leads to ambiguity and 
hesitation, and hence to difficulty in choosing a 
therapeutic approach, as in the patient we described. 
[30]. The role of SUNN (sentinel lymph node biopsy) 
continues to be studied, and its use is currently 
recommended for Stage IB and Stage II melanomas 
[29]. In some cases, preoperative high-frequency 
ultrasound diagnosis helps determine the limits of 
surgical margins, indications for lymph node biopsy, 
and the need for re-excision [31]. 
In the event of hesitation, One step melanoma 
surgery (OSMS) is found to be a very useful 
approach, since it clearly defines the surgical safety 
margins in a) melanoma in situ resection with 1 cm 
surgical safety margin, b) tumours 1 to 2 mm thick 
resection with 1 cm surgical safety margin, and c) 
thickness of 2 to 4 mm – 2 cm surgical safety margin, 
where, in the event of b) and c), it is obligatory or 
highly recommended to perform, simultaneously or in 
parallel, detection and removal of the draining lymph 
node (regardless of whether the node is 
echographically enlarged); d) tumour thickness above 
4 mm – resection with 2 cm in all directions and if 
there are no enlarged lymph nodes, 2 cm resection is 
sufficient, together with control/instrumental 
examinations every two months, but in the presence 
of enlarged lymph nodes, it is recommended that they 
will be removed and examined for the BRAF 
V600mutation, followed by computed tomography 
scan (CT) with contrast or PET scan. Interestingly, the 
abovementioned guidelines for One step melanoma 
surgery do not change and completely overlap with 
AJCC recommendations (relative to the result or 
efficiency score), however OSMS is a less traumatic 
method requiring additional preoperative preparation 
and judgment [32], [33], [34], [35], [36]. 
It is believed that in the case of melanomas 
with a thickness of over 4mm ELND is not of 
paramount importance as the draining lymph nodes 
may not be affected [32]. The reasons for this may be 
different: 1) accessory parallel lymphatic pathways 
available, on the one hand, and the other; 2) tumour 
cells may have passed the draining lymph node 
without stopping there, or there has already been 
primary haematogenous dissemination without 
involving the lymph nodes and pathways [32]. 
However, it should be taken into account that OSMS 
applies to all melanoma patient groups, which makes 
it more appropriate therapeutic endpoint [32]. 
One stage melanoma surgery results in a 
reduction of the number of steps of the so-called 
melanoma treatment programs by reducing the 
number of stages in which an error (or deviation from 
the guidelines) could occur [35]. Meanwhile, OSMS 
saves the patients repeated surgical interventions and 
relieved them emotionally and financially [32], [36], 
[37]. 
In conclusion, one step melanoma surgery is 
an approach with clearly defined surgical safety (in all 
melanoma patient groups) and behaviour against 
draining lymph nodes based on the preoperative 
ultrasound tumour thickness or clinical and 
dermatoscopic judgement (when the latter are 
explicitly in favour of thin melanoma diagnosed in 
certain patients). It is a better therapeutic solution for 
all cutaneous melanoma patient groups that allows for 
the best control of the disease within one surgical 
session. The case is indicative of the errors or 
omissions resulting from surgical treatment 
approaches recommended or not fully defined by 
AJCC. Or, if we need to be even more precise, this 
case is indicative of the risks that arise during a 
possible two-step or two-stage surgical approach. 
In the One step melanoma surgery, these 
possibilities are virtually non-existent, they are limited 
to the absolute minimum by the creation of certain 
algorithms. Optimising surgical approaches is a 
personal choice for the clinician. When guidelines are 
not so strict and precise, they provide an unjustified 
field of freedom for the clinician’s actions, and this 
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may be confusing for the patients themselves. Thus, 
there is an increased possibility of inadequate and 
unexplained approaches or solutions (as the case we 
have described). This is also the reason why some 
dermatologists in the relevant units are increasingly 
using the recommendations for OSMS that limit the 
clinician’s freedom of action but also refine his/her 
actions. Or reduce the possibilities for errors. 
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